Nexvet Biopharma plc 4
4 · Nexvet Biopharma plc · Filed Jul 5, 2017
Insider Transaction Report
Form 4
HORN JURGEN
Chief Product Development Ofcr
Transactions
- Exercise/Conversion
Restricted Share Units
2017-07-01−15,750→ 47,250 totalExercise: $0.13From: 2017-07-01Exp: 2021-07-01→ Ordinary Shares (15,750 underlying) - Exercise/Conversion
Ordinary Shares
2017-07-01$0.13/sh+15,750$1,969→ 15,750 total
Footnotes (1)
- [F1]15,750 of the Restricted Share Units vested and became convertible on 7/1/17 and 15,750 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.